Abemaciclib

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Abemaciclib
   1. Pharmacist Assessment Report
   2. Abemaciclib
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Abemaciclib

Summary

The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Abemaciclib, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.

Quick overview

Item	Content
Known uses recorded for this drug	1
Canada Market Status	Marketed (marketed DINs: 4 of 4)
Number of DINs	4 (marketed: 4)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
breast neoplasms	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02487101	VERZENIO		Valid
02487098	VERZENIO		Valid
02487136	VERZENIO		Valid
02487128	VERZENIO		Valid

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (CDK4/6 kinase inhibitor), not a conventional cytotoxic
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions (typically blood counts, liver and renal function)
Handling Protection	Please refer to the package insert warnings and precautions

---

Safety Considerations

• Drug Interactions: The interaction screen returned 100 potential interactions. The first 20 reviewed include several rated Major: clarithromycin, cobicistat, deferiprone, samarium (153Sm) lexidronam and lumacaftor. Many others are rated Moderate, including aprepitant, clotrimazole, dexamethasone, metformin, fluconazole, erythromycin, chloramphenicol, ticagrelor and roflumilast.
• Other literature signals (from literature retrieved for other predicted indications): reports on CDK4/6 inhibitors describe QTc prolongation, thromboembolic events (specifically noted with abemaciclib), atrial arrhythmias and kidney injury signals. These matter if long-term use in a non-oncology population is considered.

Package insert warnings and contraindications were not available for this report; please refer to the package insert for full safety information.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---